Bioxytran Inc Stock Price, News & Analysis

Bioxytran (OTCQB: BIXT) announced on October 29, 2025 the completion of a randomized, double-blind, placebo-controlled dose-optimization trial for its oral broad-spectrum antiviral candidate ProLectin-M. The company says prior Phase 2 results showed treated participants reached undetectable PCR viral levels in less than one week. Data from the new trial will be used to inform a phase 3 trial design for CDSCO and will be submitted to the FDA at the agency's request. Bioxytran expects to compile detailed safety and efficacy endpoints for peer-reviewed publication and plans to submit full results in the coming weeks.

Bioxytran (OTCQB: BIXT) announced a significant scientific advancement with the publication of a groundbreaking book by Prof. Avraham Mayevsky on tissue oxygenation and mitochondrial function. The research highlights the limitations of current peripheral oxygen measurements and introduces a paradigm shift towards tissue-specific oxygenation monitoring.

The company's MDX Viewer technology, combined with their Universal Oxygen Carrier (UOC) and BXT-25 development programs, aims to revolutionize treatment approaches for conditions like stroke and Alzheimer's disease. The technology will serve as a crucial biomarker in upcoming BXT-25 clinical trials, potentially transforming how oxygen delivery is measured and managed in critical conditions.

Bioxytran (OTCQB: BIXT) has announced significant progress in developing ProLectin-M, its broad-spectrum antiviral drug. The company has completed dosing in its dose optimization clinical trial, marking a crucial milestone in the drug's development.

ProLectin-M targets galectin fold on viral spike proteins and has shown impressive clinical results: 100% response rate (negative PCR tests) by day 7 and 88% response rate by day 3 in double-blinded placebo-controlled trials. The drug has demonstrated effectiveness against SARS-CoV-2, influenza, and RSV, with no viral rebounds during the 14-day observation period.

The drug's development, supported by an active FDA IND application, utilizes proprietary linear complex carbohydrate structures designed with nuclear magnetic resonance and AI to neutralize viral infectiousness.

Bioxytran (OTCQB: BIXT) has secured a GMP quality source of camel hemoglobin through a partnership with the Heme Foundation in a $10 million Joint Venture to develop a Universal Oxygen Carrier (UOC). Camel hemoglobin was chosen for its unique properties, including higher stability, resilience, and concentration compared to cow hemoglobin, with no risk of mad cow disease. The partnership grants Bioxytran full intellectual property rights for UOC development, which could enhance their leading oxygen transport molecule BXT-25, designed to treat conditions like stroke, dementia, Traumatic Brain Injury, and Alzheimer's Disease. This supply agreement represents a strategic milestone that could accelerate non-dilutive funding and advance oxygen transport technology development.

Bioxytran (OTCQB: BIXT) announced the publication of a groundbreaking book by Science Advisor Prof. Avraham Mayevsky focusing on Mongolian Gerbil brain research, which validates their clinical development program for stroke and Alzheimer's treatment. The research centers on their universal oxygen carrier (UOC) technology and FDA-approved MDX Viewer for measuring tissue oxygenation. The UOC aims to replace hyperbaric oxygen treatment by delivering therapeutic oxygen at the cellular level, avoiding harmful reactive oxygen species. The Mongolian gerbil model is particularly valuable due to its unique brain vasculature that lacks compensatory mechanisms during stroke, making it ideal for studying stroke pathophysiology and testing treatment efficacy.

Bioxytran's (OTCQB: BIXT) antiviral compound PHM23 has been selected for inclusion in the University of Georgia's grant submission to the USDA's $100 million HPAI Poultry Innovation Grand Challenge. The selection highlights PHM23's potential to combat Bird Flu (H5N1) through its galectin antagonist mechanism. The drug works by blocking viral spike proteins from attaching to host cells, demonstrating broad-spectrum antiviral activity in in vitro studies. This recognition from a leading poultry health institution validates Bioxytran's technology platform and positions PHM23 as a promising solution for addressing viral threats in the poultry industry, which faces billions in annual losses due to H5N1 outbreaks.

Bioxytran (OTCQB: BIXT) has successfully completed the dose optimization study for its antiviral drug ProLectin-M in a randomized double-blind placebo-controlled trial. The study evaluated multiple doses over 5 days with a primary endpoint of achieving undetectable viral load by Day 7. Secondary endpoints included early viral clearance assessment and symptom improvement using WHO Clinical Progression Scale. Previous trials showed promising results with 100% responder rate by Day 7 and 88% responder rate by Day 3. The data will support submissions to both FDA and CDSCO, while informing future trials for various viral indications including COVID-19, Influenza, RSV, and EBV. The company plans to complete data analysis and submit findings for additional pivotal trials.

Bioxytran (OTCQB: BIXT) commemorates 50 years of mitochondrial research advancement, highlighting the historical significance of fiber optic-based fluorometry in brain mitochondrial research through a landmark paper by Prof. Avraham Mayevsky of Bar-Ilan University.

The company's lead drug candidate BXT-25 is advancing toward Phase 1 trials, targeting conditions requiring oxygen transport carrier capabilities, including:

• Ischemic stroke
• Heart attack
• Pulmonary embolism
• Chronic kidney disease (CKD)
• Long Covid

The research emphasizes real-time mitochondrial monitoring through the MDX Viewer, an FDA-approved device measuring tissue metabolic score. The company is exploring partnerships to integrate next-generation monitoring technologies for patient selection and vital sign measurements.

Bioxytran (OTCQB: BIXT) has signed a Non-Disclosure Agreement with the University of Georgia to evaluate its galectin antagonists as a potential treatment for bird flu in chickens. The research collaboration will be led by Dr. Daniel Perez, an expert in virology and poultry medicine who serves as CVI Affiliated Faculty and Caswell Eidson Chair in Poultry Medicine at the university.

The company's leading drug candidate, ProLectin-M, is a galectin antagonist designed to fight viral infections by targeting galectins - proteins involved in viral replication, inflammation, and fibrosis. The drug has shown promise in in vitro studies against viruses similar to the bird flu virus, suggesting potential applications in poultry treatment.